IL317445A - Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use - Google Patents
Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of useInfo
- Publication number
- IL317445A IL317445A IL317445A IL31744524A IL317445A IL 317445 A IL317445 A IL 317445A IL 317445 A IL317445 A IL 317445A IL 31744524 A IL31744524 A IL 31744524A IL 317445 A IL317445 A IL 317445A
- Authority
- IL
- Israel
- Prior art keywords
- irak4
- conjugation
- degradation
- methods
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022097833 | 2022-06-09 | ||
| CN2022128219 | 2022-10-28 | ||
| CN2023093639 | 2023-05-11 | ||
| PCT/CN2023/099146 WO2023237049A1 (en) | 2022-06-09 | 2023-06-08 | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317445A true IL317445A (en) | 2025-02-01 |
Family
ID=89117516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317445A IL317445A (en) | 2022-06-09 | 2023-06-08 | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250195513A1 (en) |
| EP (1) | EP4536664A4 (en) |
| JP (1) | JP2025519417A (en) |
| KR (1) | KR20250022796A (en) |
| CN (2) | CN119403805A (en) |
| AR (1) | AR129567A1 (en) |
| AU (1) | AU2023282477A1 (en) |
| CA (1) | CA3258387A1 (en) |
| CL (1) | CL2024003737A1 (en) |
| CO (1) | CO2024018066A2 (en) |
| IL (1) | IL317445A (en) |
| MX (1) | MX2024015184A (en) |
| TW (1) | TW202413351A (en) |
| WO (1) | WO2023237049A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4613748A1 (en) * | 2022-11-04 | 2025-09-10 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Irak4 degradation agent and use thereof |
| EP4428134A1 (en) * | 2023-03-10 | 2024-09-11 | Dark Blue Therapeutics Ltd | Protac degraders of mllt1 and/or mllt3 |
| EP4656640A4 (en) * | 2023-03-03 | 2026-08-19 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | IRAQ-4 DEMOCRAFT AND USE OF IT |
| US20240374588A1 (en) * | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
| KR20260005340A (en) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | Tricyclic compounds, methods for preparing the same, and applications thereof |
| KR20260048566A (en) * | 2023-07-13 | 2026-04-10 | 인크레랜드 | Aromatic compounds, pharmaceutical compositions containing the same, and uses thereof |
| CN122270449A (en) * | 2023-12-13 | 2026-06-23 | 百济神州(苏州)生物科技有限公司 | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use |
| WO2025149070A1 (en) * | 2024-01-10 | 2025-07-17 | 甘李药业股份有限公司 | Synthesis and use of novel proteolysis chimera compound targeting interleukin-1 receptor-associated kinase 4 (irak4) |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| WO2026061418A1 (en) | 2024-09-18 | 2026-03-26 | Beone Pharmaceutical (Suzhou) Co., Ltd. | Dual irak1/irak4 degraders, compositions thereof, and methods of treatment therewith |
| WO2026158660A1 (en) * | 2025-01-26 | 2026-07-30 | 甘李药业股份有限公司 | Compound for targeted degradation of irak4 protein and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11065231B2 (en) * | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| AU2019389174A1 (en) * | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) * | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021127278A1 (en) * | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US20230122219A1 (en) * | 2020-02-03 | 2023-04-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN114437035A (en) * | 2020-11-06 | 2022-05-06 | 海思科医药集团股份有限公司 | Compound for inhibiting and degrading IRAK4, pharmaceutical composition and pharmaceutical application thereof |
| WO2023055952A1 (en) * | 2021-09-29 | 2023-04-06 | C4 Therapeutics, Inc. | Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds |
-
2023
- 2023-06-08 CN CN202380045611.5A patent/CN119403805A/en active Pending
- 2023-06-08 CA CA3258387A patent/CA3258387A1/en active Pending
- 2023-06-08 CN CN202510774453.8A patent/CN120865210A/en active Pending
- 2023-06-08 KR KR1020257000734A patent/KR20250022796A/en active Pending
- 2023-06-08 EP EP23819213.2A patent/EP4536664A4/en active Pending
- 2023-06-08 TW TW112121366A patent/TW202413351A/en unknown
- 2023-06-08 JP JP2024571353A patent/JP2025519417A/en active Pending
- 2023-06-08 AR ARP230101469A patent/AR129567A1/en unknown
- 2023-06-08 IL IL317445A patent/IL317445A/en unknown
- 2023-06-08 WO PCT/CN2023/099146 patent/WO2023237049A1/en not_active Ceased
- 2023-06-08 AU AU2023282477A patent/AU2023282477A1/en active Pending
-
2024
- 2024-12-05 CL CL2024003737A patent/CL2024003737A1/en unknown
- 2024-12-06 MX MX2024015184A patent/MX2024015184A/en unknown
- 2024-12-06 US US18/972,490 patent/US20250195513A1/en active Pending
- 2024-12-26 CO CONC2024/0018066A patent/CO2024018066A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023237049A1 (en) | 2023-12-14 |
| JP2025519417A (en) | 2025-06-26 |
| KR20250022796A (en) | 2025-02-17 |
| CN120865210A (en) | 2025-10-31 |
| CN119403805A (en) | 2025-02-07 |
| EP4536664A1 (en) | 2025-04-16 |
| EP4536664A4 (en) | 2026-08-19 |
| AU2023282477A1 (en) | 2024-12-19 |
| CA3258387A1 (en) | 2023-12-14 |
| MX2024015184A (en) | 2025-02-10 |
| CL2024003737A1 (en) | 2025-04-21 |
| TW202413351A (en) | 2024-04-01 |
| US20250195513A1 (en) | 2025-06-19 |
| CO2024018066A2 (en) | 2025-01-13 |
| AR129567A1 (en) | 2024-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL326350A (en) | Benzopyridinones and benzopyrimidinones as PI3K inhibitors | |
| AU2024314618A1 (en) | Pi3k inhibitors and use thereof | |
| MX2024015184A (en) | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use | |
| SG11202106478UA (en) | Compositions for increasing half-life of a therapeutic agent in canines and methods of use | |
| EP3897670A4 (en) | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS | |
| IL179514A0 (en) | Method of administering and using vegf inhibitors for the treatment of malignant pleural effusion | |
| IL314415A (en) | 2-substituted thiazole hsd17b13 inhibitors and uses thereof | |
| IL287220B2 (en) | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination | |
| CA3251244A1 (en) | Pi3k.alpha. inhibitors and methods of use thereof | |
| IL289758A (en) | Proportin inhibitors for use in the prevention and treatment of kidney damage | |
| IL289127A (en) | Ppm1a inhibitors and methods of using same | |
| SG11202009966SA (en) | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer | |
| GB202307609D0 (en) | Methods and composition for kras modifications | |
| HK40120789A (en) | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use | |
| EP3952871A4 (en) | AKT DEGRADATION BY CONJUGATION OF ATP COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE | |
| WO2021067572A3 (en) | Compositions and methods for inhibiting carp-1 binding to nemo | |
| CA3265397A1 (en) | Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction | |
| EP3962480A4 (en) | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | |
| IL289184A (en) | Compositions and methods for preventing and/or reducing melanosis in crustaceans | |
| IL286699A (en) | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers | |
| HK40007999A (en) | Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use | |
| HK40008079A (en) | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use | |
| EP4021956A4 (en) | METHODS FOR REDUCING ALDEHYDE EMISSIONS IN POLYETHER POLYOLS AND POLYURETHANE FOAM | |
| HK40118338A (en) | Irak4 degradation agent and use thereof | |
| GB201903349D0 (en) | Seawater treatment and injection platform |